HuGE Literature Finder
Records
1
-
3
CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients. Journal of neuroimmunology 2021 Jun 355 577571. Fan Zhirong, Zheng Deqiang, Wen Xinmei, Shen Faxiu, Lei Lin, Su Shengyao, Zhang Shu, Liu Qing, Zhang Xueping, Lu Yan, Di Li, Shen Xin-Ming, Da Yuw |
Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis. European journal of neurology 2018 Aug 25 (8): 1049-e80. Chen D, Hou S, Zhao M, Sun X, Zhang H, Yang |
Monitoring of peripheral blood cluster of differentiation 4 adenosine triphosphate activity and CYP3A5 genotype to determine the pharmacokinetics, clinical effects and complications of tacrolimus in patients with autoimmune diseases. Experimental and therapeutic medicine 2018 Jan 15 (1): 532-538. Muraki Yuichi, Mizuno Shugo, Nakatani Kaname, Wakabayashi Hiroki, Ishikawa Eiji, Araki Toshimitsu, Taniguchi Akira, Isaji Shuji, Okuda Masahi |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 01, 2023
- Content source: